Relationship between nm23H1 genetic instability and clinical pathological characteristics in Chinese digestive system cancer patients

Table 1 Relationship between clinical pathological parameters and nm23H1 genetic instability in gastric cancer

Clinical pathological factors	Cases (n)	MSI+ (%)	LOH+ (%)	nm23H1+ (%)	nm23H1 expression intensity (mean ± SD)
Histological type	40	8 (20.00)	7 (17.50)	22 (55.00)	40.63 ± 2.95
Tubular adenocarcinoma	33	7 (22.21)	6 (18.18)	21 (63.64)	41.56 ± 2.78
High differentiation	10	3 (30.00)	1 (10.00)	10 (100.00)	41.83 ± 1.52
Middle differentiation	15	3 (20.00)	2 (13.33)	9 (60.00)	40.69 ± 2.35
Low differentiation	8	1 (12.50)	3 (37.50)	2 (25.00)1	41.43 ± 1.89
Mucoid adenocarcinoma	7	1 (14.29)	1 (14.29)	1 (14.29)2	39.87 ± 2.31
Serosa infiltration
Positive	24	3 (12.50)	6 (25.00)	10 (41.67)	39.76 ± 2.64
Negative	16	5 (31.25)	1 (6.25)	12 (75.00)3	41.45 ± 2.23
Lymph node metastasis
Positive	20	1 (5.00)	6 (30.00)	6 (30.00)	39.14 ± 2.34
Negative	20	7 (35.00)4	1 (5.00)5	16 (80.00)6	41.75 ± 1.65
TNM stage
I+ II	22	7 (31.82)	1 (4.55)	17 (77.27)	41.22 ± 1.87
III + IV	18	1 (5.56)7	6 (33.33)8	5 (17.86)9	40.13 ± 2.35

¹P < 0.0001 vs differentiation degree of tubular adenocarcinoma;

²P = 0.017 vs tubular adenocarcinoma;

³P = 0.039 vs positive serosa infiltration;

⁴P = 0.017,

⁵P = 0.038,

⁶P = 0.001 vs negative lymph node metastasis;

⁷P = 0.04,

⁸P = 0.017,

⁹P = 0.001 vs TNM stage I+ II.

Table 2 Relationship between MSI, LOH and nm23H1 protein expression in different cancers of digestive system

Group	Positive frequency of nm23H1 protein % (n/n)
	Gastric cancer	Colon cancer	HCC	Gallbladder cancer
MSI positive	87.50 (7/8)	75.00 (6/8)	83.33 (5/6)	63.64 (7/11)
MSI negative	46.88 (15/32)1	45.45 (10/22)	52.38 (22/42)	41.67 (15/36)
LOH positive	14.29 (1/7)	33.33 (2/6)	27.27 (3/11)	11.11 (1/9)
LOH negative	63.64 (21/33)2	58.33 (14/24)	64.86 (24/37)3	55.26 (21/38)4

¹P = 0.04 vs MSI positive group;

²P = 0.017,

³P = 0.027,

⁴P = 0.016 vs LOH positive group.

Table 3 Relationship between MSI, LOH and nm23H1 protein expression in different cancers of digestive system (mean ± SD)

Group	nm23H1 protein expression intensity (n = 10)
	Gastric cancer	Colon cancer	HCC	Gallbladder cancer
MSI positive	26.34 ± 2.17	29.34 ± 2.14	29.34 ± 2.14	26.34 ± 2.17
MSI negative	25.78 ± 2.34	24.78 ± 2.06	24.78 ± 2.06	25.78 ± 2.34
LOH positive	27.64 ± 2.38	22.64 ± 2.38	22.64 ± 2.38	27.64 ± 2.38
LOH negative	25.88 ± 2.52	26.88 ± 2.52	26.88 ± 2.52	25.88 ± 2.52

Table 4 Relationship between clinical pathological parameters and nm23H1 genetic instability in colon cancer

Clinical pathological factors	Cases	MSI+ (%)	LOH+ (%)	nm23H1+ (%)	nm23H1 expression intensity (mean ± SD)
Histological type	30	8 (26.67)	6 (20.00)	16 (53.33)	40.21 ± 3.29
Tubular adenocarcinoma	25	7 (28.00)	5 (20.00)	15 (60.00)	40.76 ± 2.74
High differentiation	8	2 (25.00)	1 (12.50)	8 (100.00)	41.49 ± 2.01
Middle differentiation	13	5 (38.46)	2 (15.38)	6 (46.15)	40.41 ± 1.98
Low differentiation	4	0 (00.00)	2 (50.00)	1 (25.00)1	40.18 ± 2.17
Mucoid adenocarcinoma	5	1 (20.00)	1 (20.00)	1 (20.00)	39.53 ± 2.61
Serosa infiltration
Positive	20	7 (35.00)	3 (15.00)	12 (48.00)	41.02 ± 2.14
Negative	10	1 (10.00)	3 (30.00)	4 (40.00)	41.45 ± 2.23
Lymph node metastasis
Positive	11	1 (9.09)	5 (45.45)	3 (27.27)	39.14 ± 2.34
Negative	19	7 (36.84)	1 (5.26)2	13 (68.42)3	41.75 ± 1.65
TNM stage
I+ II	16	7 (43.75)	1 (11.76)	13 (81.25)	41.49 ± 2.01
III + IV	14	1 (7.14)4	5 (35.71)5	3 (21.43)6	39.53 ± 2.61

¹P = 0.004 vs differentiation degree of tubular adenocarcinoma;

²P = 0.003,

³P = 0.074 vs positive lymph node metastasis;

⁴P = 0.023,

⁵P = 0.046,

⁶P < 0.0001 vs TNM stage I+ II.

Table 5 Relationship between clinical pathological parameters and nm23H1 genetic instability in HCC

Clinical pathological factors	Cases	MSI+ (%)	LOH+ (%)	nm23H1+ (%)	nm23H1 expression intensity (mean ± SD)
Differentiation degree	48	6 (12.50)	11 (22.92)	27 (56.25)	25.96 ± 2.53
High differentiation	15	3 (20.00)	2 (13.33)	10 (66.67)	27.87 ± 2.83
Middle differentiation	20	2 (10.00)	5 (25.00)	12 (60.00)	22.37 ± 2.35
Low differentiation	13	1 (7.70)	4 (30.77)	5 (38.46)	22.58 ± 2.56
Liver infiltration
Positive	15	0 (00.00)	8 (53.33)	6 (40.00)	23.84 ± 2.43
Negative	33	6 (18.18)	3 (9.09)	21 (63.64)	25.63 ± 2.63
Lymph node metastasis
Positive	20	1 (5.00)	9 (45.00)	4 (20.00)	21.67 ± 2.56
Negative	28	5 (17.86)	2 (7.14)	23 (82.14)1	28.56 ± 2.01
TNM stage
I+ II	29	5 (17.24)	1 (3.45)	22 (75.86)	25.58 ± 2.33
III + IV	19	1 (5.26)	10 (52.63)2	5 (26.32)2	24.27 ± 2.27

¹P < 0.0001 vs positive lymph node metastasis;

²P < 0.0001 vs TNM stage I+ II.

Table 6 Relationship between clinical pathological parameters and nm23H1 genetic instability in gallbladder cancer

Clinical pathological factors	Cases	MSI + (%)	LOH + (%)	nm23H1 + (%)	nm23H1 expression intensity (mean ± SD)
Differentiation degree	47	11 (22.40)	9 (19.14)	22 (46.81)	25.96 ± 2.73
High differentiation	17	9 (52.94)	0 (00.00)	10 (58.82)	24.15 ± 2.49
Middle differentiation	13	2 (15.38)	3 (23.08)	7 (53.85)	27.07 ± 2.53
Low differentiation	17	0 (00.00)1	6 (35.29)2	5 (29.41)	28.03 ± 2.63
Liver infiltration
Positive	18	1 (5.56)	7 (38.89)	6 (33.33)	24.87 ± 2.83
Negative	29	10 (34.48)3	2 (6.90)4	16 (55.17)	26.37 ± 2.45
lymph node metastasis
Positive	20	1 (5.00)	8 (40.00)	5 (25.00)	23.56 ± 2.19
Negative	27	10 (37.04)5	1 (3.70)6	17 (62.96)7	26.67 ± 2.33
TNM stage
I+ II	23	10 (43.48)	0 (00.00)	15 (65.22)	24.15 ± 2.78
III + IV	24	1 (4.17)8	9 (37.50)9	7 (29.17)10	29.84 ± 2.53

¹P < 0.0001;

²P = 0.008 vs differentiation degree;

³P = 0.023;

⁴P = 0.006 vs positive liver infiltration;

⁵P < 0.0001,

⁶P = 0.001,

⁷P = 0.009 vs positive lymph node metastasis;

⁸P = 0.001;

⁹P < 0.0001;

¹⁰P = 0.013 vs TNM stage I+ II.